KDventures portfolio company Modus Therapeutics pauses enrollment in Phase 2a sevuparin trial after serious adverse event

KDventures announced October 15, 2026, that 51%-owned Modus Therapeutics temporarily paused Part 2 enrollment in its Phase 2a sevuparin trial. The study targets chronic kidney disease with anemia; the pause followed a serious adverse event in a sevuparin-treated patient. The event was reported as a suspected unexpected serious adverse reaction; a causal link to sevuparin remains unestablished. The pause was voluntary, not regulator-ordered. No ongoing treatment required discontinuation. Proof-of-concept results are now expected in the first quarter of 2027, versus around year-end 2026, pending completion of the safety assessment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein. (C)